Cita APA

Fiedler, W. M., Conte, G. D., Macchini, M., Matos Garcia, I., Habel, B., Saavedra Gadea, O., . . . Ochsenreither, S. (2022). Safety and preliminary activity results of the GATTO study, a phase Ib study combining the anti-TA-MUC1 antibody gatipotuzumab with the anti-EGFR tomuzotuximab in patients with refractory solid tumors.

Citación estilo Chicago

Fiedler, W. M., G. D. Conte, Marina Macchini, Ignacio Matos Garcia, B. Habel, Omar Saavedra Gadea, Elena Garralda Cabanas, y Sebastian Ochsenreither. Safety and Preliminary Activity Results of the GATTO Study, a Phase Ib Study Combining the Anti-TA-MUC1 Antibody Gatipotuzumab With the Anti-EGFR Tomuzotuximab in Patients With Refractory Solid Tumors. 2022.

Cita MLA

Fiedler, W. M., et al. Safety and Preliminary Activity Results of the GATTO Study, a Phase Ib Study Combining the Anti-TA-MUC1 Antibody Gatipotuzumab With the Anti-EGFR Tomuzotuximab in Patients With Refractory Solid Tumors. 2022.